Oxprenolol in clinical practice.
Oxprenolol is a potent noncardioselective beta-adrenoceptor blocking drug with partial agonist activity of proved efficacy and high tolerability in patients at risk of various cardiovascular disease syndromes. The drug rapidly relieves angina and attenuates the electrocardiographic evidence of myocardial ischemia. It is a potent antihypertensive drug that not only reduces the blood pressure at rest but also prevents the surges associated with exercise and psychic stress. Oxprenolol has substantial benefit in the alleviation of many of the somatic sequelae of psychic stress and anxiety. The drug also suppresses the cardiovascular and metabolic effects of cigarette smoking. In the field of primary prevention, oxprenolol has attributes that could be expected to reduce the long-term cardiovascular complications of high blood pressure. In the secondary prevention, it reduces the further incidence of sudden death in patients in whom administration is started in relatively small doses within a few weeks after acute myocardial infarction. In the 15 years that the drug has been available for clinical prescription, it has established a reputation for high clinical tolerability.
D000787:Angina Pectoris / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D010096:Oxprenolol / Q000627:therapeutic use*; D011322:Primary Prevention / Q000379:methods; D012306:Risk
D010096:Oxprenolol